| Not Yet Recruiting | Comparing the Efficacy and Safety of Different Postoperative Adjuvant Regimens in Patients With Resectable Ade Gastric / Gastroesophageal Junction Adenocarcinoma | Phase 4 | 2025-09-30 |
| Not Yet Recruiting | Comparing the Efficacy and Safety of Chemotherapy Combined With or Without Immunotherapy as Postoperative Adju Gastric / Gastroesophageal Junction Adenocarcinoma | Phase 4 | 2025-08-31 |
| Not Yet Recruiting | Comparing the Efficacy and Safety of Chemotherapy Combined With or Without Immunotherapy as an Adjuvant Treatm Gastric / Gastroesophageal Junction Adenocarcinoma | Phase 4 | 2025-08-31 |
| Not Yet Recruiting | Integrating Surgery and Radiotherapy Following Tislelizumab-based Conversion Therapy in N3-Stage III NSCLC Non-Small Cell Lung Cancer (Stage III) | Phase 2 | 2025-03-31 |
| Not Yet Recruiting | Tislelizumab Combined with SOX Regimen in the Treatment of Locally Advanced Gastric Cancer/gastroesophageal Ju Gastric/Gastroesophageal Junction Adenocarcinoma | Phase 2 | 2024-12-30 |
| Not Yet Recruiting | Adebrelimab Plus Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC Harboring Driver Gene Mutations Non Small Cell Lung Cancer | Phase 2 | 2024-04-15 |
| Recruiting | Observation on the Therapeutic Effect of Huaier Granules in the Adjuvant Treatment of Non-small Cell Lung Canc Non-small Cell Lung Cancer | — | 2024-03-21 |
| Unknown | Zanubrutinib Combined With R-CHOP Regimen in the Treatment of Newly Diagnosed DLBCL With High-risk Factors Diffuse Large B Cell Lymphoma | Phase 2 | 2023-08-01 |
| Unknown | Quintuple Method for Treatment of Multiple Refractory Colorectal Liver Metastases For Patients With Colorectal Cancer Liver Metastases Who Were Not Able to Curative Surgical Resection.Focused on the Treatment Effect With the Quintuple Method | Phase 2 | 2023-03-15 |
| Not Yet Recruiting | Early Blocking Strategy for Metachronous Liver Metastasis of Colorectal Cancer Based on Pre-hepatic CTC Detect Preventive Effect of Quintuple Therapy on Metachronous Liver Metastases in Patients With Colorectal Cancer | Phase 2 | 2023-03-01 |
| Completed | Real-world Study of Inetetamab in HER2-positive Metastatic Breast Cancer HER2-positive Metastatic Breast Cancer | — | 2022-07-01 |
| Unknown | AK105 Plus Anlotinib Hydrochloride Combined With Albumin Paclitaxel as a First-line Therapy in Patients With A Breast Neoplasm Female | Phase 2 | 2022-07-01 |
| Unknown | Clinical Study of Fulvestrant Combined With Chidamide in the Treatment of Hormone Receptor-positive Advanced B Breast Cancer | Phase 4 | 2022-02-07 |
| Not Yet Recruiting | Neoadjuvant Icotinib With Chemotherapy for Epidermal Growth Factor Receptor(EGFR)-Mutated Resectable Lung Aden NSCLC, EGF-R Positive Non-Small Cell Lung Cancer | Phase 2 | 2022-01-01 |
| Unknown | Clinical Study of Chidamide Combined With Fulvestrant in the Treatment of Hormone Receptor-positive Advanced B Advanced Breast Cancer | N/A | 2021-08-18 |
| Completed | To Evaluate Thrombosis Risk in Chemotherapy Patients With Solid Tumors Who Receiving Thrombocytopenia Treatmen Chemotherapy-induced Thrombocytopenia | — | 2020-09-02 |
| Unknown | Combined Use of Apatinib Mesylate and Vinorelbine Versus Single Use of Vinorelbine in Triple-negative Breast C Triple-negative Breast Cancer | Phase 2 | 2019-06-24 |
| Unknown | Anlotinib Hydrochloride Combined With Epirubicin and Ifosfamide for Soft Tissue Sarcoma Patients Sarcoma, Soft Tissue | Phase 2 | 2019-05-20 |
| Unknown | Irinotecan for Advanced and Metastatic Breast Cancer Breast Cancer | Phase 2 | 2017-04-01 |
| Unknown | A Phase II Study of Irinotecan in 3 Line or More Therapy in Local Recurrence or Metastatic Breast Cancer Stage IIIB, IV, Recurrent, and Metastatic Breast Cancer | Phase 2 | 2014-09-01 |
| Unknown | Bevacizumab Therapy Untreated Unresectable Liver Metastases From Colorectal Cancer Liver Metastases, Colorectal Cancer | Phase 2 | 2012-09-01 |